What neurotransmitter do NK1 receptor antagonists block to reduce nausea?

Study Pharmacology Antiemetic Agents. Use flashcards and multiple choice questions with hints and explanations. Prepare for success!

Multiple Choice

What neurotransmitter do NK1 receptor antagonists block to reduce nausea?

Explanation:
NK1 receptor antagonists primarily target and block the action of Substance P, a neuropeptide that plays a crucial role in the signaling pathways associated with pain and nausea. By inhibiting Substance P from binding to its receptors in the central nervous system, particularly in the area postrema of the brain, these antagonists effectively help to reduce the sensation of nausea and prevent vomiting. Substance P is involved in the vomiting reflex and is released in response to various stimuli, including chemotherapy, motion sickness, and other triggers. Thus, by blocking its effects, NK1 receptor antagonists are particularly useful in treating nausea and vomiting associated with chemotherapy and other conditions. This specific mechanism of action highlights the importance of the NK1 receptor in the modulation of emesis, making it a targeted approach in antiemetic therapy.

NK1 receptor antagonists primarily target and block the action of Substance P, a neuropeptide that plays a crucial role in the signaling pathways associated with pain and nausea. By inhibiting Substance P from binding to its receptors in the central nervous system, particularly in the area postrema of the brain, these antagonists effectively help to reduce the sensation of nausea and prevent vomiting.

Substance P is involved in the vomiting reflex and is released in response to various stimuli, including chemotherapy, motion sickness, and other triggers. Thus, by blocking its effects, NK1 receptor antagonists are particularly useful in treating nausea and vomiting associated with chemotherapy and other conditions. This specific mechanism of action highlights the importance of the NK1 receptor in the modulation of emesis, making it a targeted approach in antiemetic therapy.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy